MedBen Rx
  • About Us
  • Genomic Testing
  • Resources
    • MedBen Rx Blog
    • Online Services & Forms
  • Contact Us
  • MedBen Access
  • MedBen.com
Select Page

Major PBMs Are Blocking Biosimilar Savings, but MedBen Rx Offers a Better Path

Jul 29, 2025 | Biologics, Biosimilar, Cost Savings, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Savings

The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow… in no small part because major PBMs are stifling uptake....

Price Check: How the U.S. Compares Globally on Prescription Costs

Jun 16, 2025 | Drug costs, Pharmacies, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs

A recent Statista article examines the disparity in prescription drug spending across countries. The Organisation for Economic Co-operation and Development (OECD) ranks the United States highest in average spending, at $1,218 per resident – over $200 more than...

Momentum Grows Against PBM-Owned Pharmacies

May 5, 2025 | Legislation, News, Pharmacies, Pharmacy Benefits Manager (PBM), State legislation

On April 16, Arkansas became the first state to ban pharmacy benefit managers (PBMs) from acquiring an interest in – or otherwise directly or indirectly holding a permit for the retail sale of – prescription drugs, including mail-order...

JPMorgan Sued for Allowing Inflated Drug Prices through its PBM

Mar 24, 2025 | Drug costs, Lawsuits, News, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs

Current and former employees are suing the financial services firm JPMorgan for allowing inflated drug prices through its partnership with pharmacy benefits manager (PBM) CVS Caremark. The plaintiffs claim that poor PBM oversight led to unnecessarily high prescription...

Major PBMs Pocketed Nearly $9 Billion through Specialty Drug Pricing Practices, FTC Finds

Jan 27, 2025 | Federal Trade Commission (FTC), MedBen Rx, News, Pharmacy Benefits Manager (PBM), Rx Costs, Specialty Drugs, Spread Pricing

Through specialty generic drug markups, three major pharmacy benefit managers (PBMs) earned a collective $7.3 billion above estimated acquisition costs over a five-year period, according to an interim report released by the Federal Trade Commission (FTC)....

FTC Accuses Major PBMs of Overcharging Clients

Jul 23, 2024 | Federal Trade Commission (FTC), Formularies, News, Pharmacy Benefits Manager (PBM)

In an interim report released on July 9, the Federal Trade Commission charges major pharmacy benefit managers of engaging in business practices designed to benefit their own bottom lines at the expense of clients. The FTC report, subtitled “The Powerful...
« Older Entries

Categories

  • 340B
  • Access solution
  • Access solutions
  • Acquisition Cost Index (ACI)
  • Affordable Care Act
  • Anniversaries
  • Announcements
  • Appropriateness Solutions
  • Avande
  • Average Wholesale Price
  • Benefits Advisory Conference
  • Benefits preservation
  • Biologics
  • Biosimilar
  • Brand Name Drugs
  • Brian Fargus
  • Cancer
  • Caroline Fraker
  • Case Study
  • Cholesterol
  • Claims
  • Client Report
  • Comparative Effectiveness
  • Compliance
  • Consolidated Appropriations Act of 2021 (CAA)
  • Cost Plus
  • Cost Plus Pricing
  • Cost projections
  • Cost Savings
  • Diabetes
  • Discounts
  • Doug Freeman
  • Drug costs
  • Drug makers
  • Drug marketing
  • Drug reimportation
  • Evidence-based research
  • Federal Trade Commission (FTC)
  • Food and Drug Administration (FDA)
  • Formularies
  • Fraud
  • Gene therapy
  • Generic Drugs
  • Genetic testing
  • Genomics
  • GLP-1s
  • Government
  • Guarantees
  • Health and Human Services
  • Health systems
  • Heart medications
  • High-value formulary
  • History
  • Humalog
  • Humira
  • Idacio
  • Inflation
  • Kurt Harden
  • Lawsuits
  • Legislation
  • Limited Use HRA
  • Lobbying
  • Luke Burchard
  • MDMA (ecstasy)
  • MedBen
  • MedBen Access
  • MedBen Basics
  • MedBen Board of Directors\
  • MedBen employees
  • MedBen Rx
  • MedBen Rx Advocate
  • MedBen Rx Alliance
  • MedBen Rx News
  • MedBen University
  • Medicare
  • Mobile app
  • Mounjaro
  • News
  • Nutrigenomics
  • Online Services
  • Opinions
  • Outcomes
  • Overprescribing
  • Own Use
  • Ozempic
  • Patient advocacy program
  • Perigon Pharmacy 360
  • Pharmacies
  • Pharmacogenomics
  • Pharmacy Benefits Manager (PBM)
  • Pharmacy Services Administrator (PSA)
  • Precision medicine
  • Prescription drugs
  • Prescription Portal
  • Pricing solutions
  • Psychedelic drugs
  • Rebates
  • Regulatory
  • Reporting
  • Research
  • Rx Advertising
  • Rx Costs
  • Rx Facts
  • Rx prices
  • Rx Spending
  • RxDC report
  • Savings
  • Specialty Drugs
  • Spread Pricing
  • State legislation
  • Statins
  • Stelara
  • Study
  • Surveys
  • Transparency
  • Trend
  • TruDataRx
  • Trulicity
  • Value
  • Ventegra
  • Wegovy
  • Weight loss
  • Weight loss drugs
  • Weight management
  • Wellness
  • White paper
  • Zepbound
  • About Us
  • Contact Us
  • Blog
  • Online Services
  • MedBen Access
  • Sitemap
  • Privacy
  • MedBen.com

Sign Up for our Newsletter

  • This field is for validation purposes and should be left unchanged.
© 2025 MedBen Rx. All rights reserved.